Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs.
Sebti
S M
SM
Department of Pharmacology, University of Pittsburgh, PA 15261, USA.
Hamilton
A D
AD
D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D004122:Dimethylallyltranstransferase / Q000037:antagonists & inhibitors*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D011905:Genes, ras; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology; D017368:Protein Prenylation; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D018631:ras Proteins / Q000378:metabolism*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009842:Oligopeptides; D004122:Dimethylallyltranstransferase; D020794:Receptor Protein-Tyrosine Kinases; D018631:ras Proteins